Neoplasms Clinical Trials in Nashville, Tennessee

43 recruitingNashville, Tennessee

Showing 120 of 43 trials

Recruiting
Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting
Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled281 locationsNCT06925737
Recruiting
Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 1Phase 2

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Neoplasms, Prostate
GlaxoSmithKline85 enrolled15 locationsNCT06990880
Recruiting
Phase 1Phase 2

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Breast CancerBreast Neoplasms
Pfizer100 enrolled166 locationsNCT06966453
Recruiting
Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled257 locationsNCT06841354
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Phase 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled163 locationsNCT07164443
Recruiting
Phase 3

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Prostate CancerProstatic Neoplasms
Clarity Pharmaceuticals Ltd383 enrolled27 locationsNCT06056830
Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC372 enrolled17 locationsNCT06797635
Recruiting

Real World Registry for Use of the Ion Endoluminal System

Lung CancerLung NeoplasmsNeoplasms+6 more
Intuitive Surgical3,000 enrolled16 locationsNCT06004440
Recruiting
Phase 2

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Breast NeoplasmsInvasive Breast Cancer
Atossa Therapeutics, Inc.87 enrolled15 locationsNCT05607004
Recruiting
Phase 1Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Phase 1

A Study of DM001 in Patients With Advanced Solid Tumors

Breast Neoplasms
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.128 enrolled5 locationsNCT06475937